Objective:

To explore the role of aldosterone synthase inhibitors (ASIs) as alternatives to mineralocorticoid receptor antagonists (MRAs) in managing cardiovascular and renal conditions, highlighting their potential advantages.

Key Findings:

• Spironolactone and eplerenone are effective but have significant side effects limiting their use, particularly hyperkalemia and sexual adverse effects.
• New nonsteroidal MRAs like finerenone show promise but have limitations including hyperkalemia, especially in patients with decreased renal function.
• ASIs have demonstrated high selectivity for CYP11B2, reducing aldosterone without impacting cortisol synthesis, which may improve patient tolerability.

Interpretation:

ASIs may provide a more effective and tolerable option for patients with conditions related to aldosterone excess, addressing the limitations of current MRAs, particularly in terms of side effects.

Limitations:

• Development of selective ASIs has been challenging due to the similarity in aldosterone and cortisol synthesis pathways, which complicates drug design.
• Some ASIs are still under development or not widely available, limiting their immediate clinical application.

Conclusion:

ASIs represent a promising therapeutic avenue for managing cardiovascular and renal diseases associated with aldosterone excess, warranting further long-term trials to fully assess their efficacy and safety.